Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 5/20 | 0.43 |
| ▸ | CCR5 | P51681 | 3/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 3/20 | 0.39 |
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL455236 | 0.93 | CCR8 (0.44) | CCR8CCR5 | |
| SCHEMBL455242 | 0.81 | MEN1 (0.43) | BCHEACHE | |
| SCHEMBL457190 | 0.80 | CCR8 (0.49) | CCR8ACHE | |
| Hydrochloric Acid SCHEMBL2831212 | 0.80 | MEN1 (0.42) | BCHEACHE | |
| Trifluoroacetic Acid SCHEMBL4717787 | 0.80 | MEN1 (0.38) | — | |
| SCHEMBL456851 | 0.80 | KDM4E (0.44) | BCHEACHE | |
| Hydrochloric Acid SCHEMBL2834368 | 0.80 | CCR8 (0.49) | CCR8ACHE | |
| SCHEMBL19432972 | 0.77 | KMT2A (0.40) | BCHEACHE | |
| Trifluoroacetic Acid SCHEMBL2836950 | 0.77 | KMT2A (0.56) | BCHEACHE | |
| Trifluoroacetic Acid SCHEMBL2837152 | 0.76 | KMT2A (0.60) | BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170258784-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2017-09-14 | — | — | US | disclosed |
| US-9694006-B2 | Use of pyrroloquinoline compounds to kill clinically latent microorganisms | HELPERBY THERAPEUTICS LIMITED (GB) | 2017-07-04 | — | — | US | disclosed |
| EP-1945211-B1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LTD (GB) | 2015-10-21 | — | — | EP | disclosed |
| US-20120231995-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2012-09-13 | — | — | US | disclosed |
| US-8207187-B2 | Use of pyrroloquinoline compounds to kill clinically latent microorganisms | HELPERBY THERAPEUTICS LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-20100093691-A1 | TOPICAL FORMULATIONS | HELPERBY THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20090137622-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258784-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | CCR8 2742/4885CCR5 1454/4885MCHR1 1410/4885 |
| US-20090137622-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | CCR8 2742/4885CCR5 1454/4885MCHR1 1410/4885 |
| US-20120231995-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | CCR8 2742/4885CCR5 1454/4885MCHR1 1410/4885 |
| US-20100093691-A1 | TOPICAL FORMULATIONS | DPM1, SUCLG1, LSS | CCR8 368/4885CCR5 666/4885MCHR1 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.